2013 Fiscal Year Final Research Report
Fate of siRNA in the lungs and optimization of siRNA inhalant formulation based on RNA interference effect
| Project/Area Number |
23590059
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Meijo University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
OKUDA Tomoyuki 名城大学, 薬学部, 助教 (20513857)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | ドラッグデリバリー / siRNA / 遺伝子治療 / 蛍光標識 / 吸入剤 / 吸入粉末剤 / 体内動態 |
|---|
| Research Abstract |
We developed Cy5.5-siRNA, that enable us to trace the fate of siRNA in a body without affecting its RNA interference effect. Adding a vector to siRNA increased the retention time of siRNA in the lungs and suppressed siRNA entering into blood. The local pulmonary administration of siRNA reduced the amount of siRNA required to express the RNA interference effect compared to the systemic administration. Regarding to the stability of Cy5.5-siRNA in a body, we developed a novel electrophoresis method that separates siRNA and Cy5.5 by using a PCI solution. The results obtained by this study will contribute greatly to the development of siRNA formulations based on the fate of siRNA in the body.
|
